Cutia Therapeutics' Topical Acne Treatment Gets China Marketing Approval

Like
Comment
Favorite

Cutia Therapeutics' Topical Acne Treatment Gets China Marketing Approval

MT Newswires Live2024-11-12

Cutia Therapeutics (HKG:2487) said its topical 4% minocycline foam obtained marketing approval from China's National Medical Products Administration, according to a Tuesday filing with the Hong Kong bourse.

The topical treatment is used to treat patients as young as nine and adults with non-nodular moderate to severe acne vulgaris, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

22:58
Li-S Energy Ltd - Collaboration With Kea Aerospace to Power High Altitude Uavs
22:56
Eurogroup Laminations Spa - Consolidated Revenues for 2024 Amounted to EUR 869.4 Mln
22:56
Eurogroup Laminations Spa - Adjusted Ebitda for 2024 Stood at EUR 116 Mln
22:56
Eurogroup Laminations Spa - Group Revenues Expected to Grow With a Cagr of 10%-15% Over 2025-2028
22:56
Eurogroup Laminations Spa - Proposed Dividend of EUR 0.042 per Share

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2482120745?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-12 13:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482120745","market":"hk","top_or_hot":-1,"title":"Cutia Therapeutics' Topical Acne Treatment Gets China Marketing Approval","media":"MT Newswires Live","content":"<html><body><p> Cutia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2487) said its topical 4% minocycline foam obtained marketing approval from China's National Medical Products Administration, according to a Tuesday filing with the Hong Kong bourse.</p><p>The topical treatment is used to treat patients as young as nine and adults with non-nodular moderate to severe acne vulgaris, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cutia Therapeutics' Topical Acne Treatment Gets China Marketing Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCutia Therapeutics' Topical Acne Treatment Gets China Marketing Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-12 13:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Cutia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2487) said its topical 4% minocycline foam obtained marketing approval from China's National Medical Products Administration, according to a Tuesday filing with the Hong Kong bourse.</p><p>The topical treatment is used to treat patients as young as nine and adults with non-nodular moderate to severe acne vulgaris, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2482120745","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482120745","pubTimestamp":1731389310,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cutia Therapeutics  said its topical 4% minocycline foam obtained marketing approval from China's National Medical Products Administration, according to a Tuesday filing with the Hong Kong bourse.The topical treatment is used to treat patients as young as nine and adults with non-nodular moderate to severe acne vulgaris, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK1161":"生物科技","02487":"科笛-B"},"translate_title":"Cutia Therapeutics的局部痤疮治疗获得中国上市批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02487":0.9,"LENZ":1},"content_text":"Cutia Therapeutics (HKG:2487) said its topical 4% minocycline foam obtained marketing approval from China's National Medical Products Administration, according to a Tuesday filing with the Hong Kong bourse.The topical treatment is used to treat patients as young as nine and adults with non-nodular moderate to severe acne vulgaris, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}